Genetic Technologies Stock Number Of Shares Shorted
| GENE Stock | USD 2.25 0.03 1.35% |
Genetic Technologies fundamentals help investors to digest information that contributes to Genetic Technologies' financial success or failures. It also enables traders to predict the movement of Genetic Stock. The fundamental analysis module provides a way to measure Genetic Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genetic Technologies stock.
Genetic | Number Of Shares Shorted |
Genetic Technologies Company Number Of Shares Shorted Analysis
Genetic Technologies' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Genetic Technologies Number Of Shares Shorted | 15.66 K |
Most of Genetic Technologies' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Genetic Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Genetic Technologies is extremely important. It helps to project a fair market value of Genetic Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Genetic Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genetic Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genetic Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Genetic Technologies has 15.66 K of outstending shares currently sold short by investors. This is 99.51% lower than that of the Life Sciences Tools & Services sector and 99.48% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 99.67% higher than that of the company.
Genetic Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.Genetic Technologies is currently under evaluation in number of shares shorted category among related companies.
Genetic Technologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Genetic Technologies from analyzing Genetic Technologies' financial statements. These drivers represent accounts that assess Genetic Technologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Genetic Technologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 685.0M | 2.4B | 784.4M | 636.2M | 731.6M | 628.9M | |
| Enterprise Value | 671.3M | 2.4B | 773.3M | 628.9M | 723.2M | 619.6M |
Genetic Fundamentals
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 256.87 M | ||||
| Shares Outstanding | 4.41 M | ||||
| Shares Owned By Institutions | 0.68 % | ||||
| Number Of Shares Shorted | 15.66 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 1.29 X | ||||
| Revenue | 8.69 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (9.24 M) | ||||
| Net Income | (11.75 M) | ||||
| Cash And Equivalents | 11.74 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 532.85 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (9.93 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 60 | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 10.43 M | ||||
| Total Asset | 14.86 M | ||||
| Retained Earnings | (156.72 M) | ||||
| Working Capital | 7.19 M | ||||
| Current Asset | 9.03 M | ||||
| Current Liabilities | 992 K | ||||
| Net Asset | 14.86 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Genetic Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Genetic Technologies' short interest history, or implied volatility extrapolated from Genetic Technologies options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Genetic Technologies Piotroski F Score and Genetic Technologies Altman Z Score analysis. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.